Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | F2R | P25116 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 7/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11126322 | 0.90 | MAPT (0.50) | MAPTPOLBATMMEN1KMT2A | |
| SCHEMBL9400557 | 0.88 | MAPT (0.51) | MAPTPOLBATMMEN1KMT2A | |
| SCHEMBL3354579 | 0.83 | MAPT (0.47) | MAPTPOLBATMMEN1KMT2A | |
| SCHEMBL10577625 | 0.82 | CDK2 (0.46) | MAPTPOLBATMMEN1KMT2A | |
| SCHEMBL3355292 | 0.81 | HTR6 (0.59) | MAPTPOLBATMMEN1KMT2A | |
| SCHEMBL20507307 | 0.80 | MAPT (0.56) | MAPTPOLBATMMEN1KMT2A | |
| SCHEMBL3352978 | 0.80 | CACNB4 (0.56) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL23525638 | 0.79 | CDK2 (0.53) | MAPTMEN1KMT2ALMNACDK2 | |
| SCHEMBL3356257 | 0.79 | CACNB4 (0.58) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL3355596 | 0.79 | ALDH1A1 (0.55) | MAPTMEN1KMT2ALMNACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-10-22 | — | — | US | disclosed |
| US-20220112160-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112160-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | KEAP1, NFE2L2, HMOX1 | MAPT 287/4885POLB 3248/4885ATM 749/4885 |
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | MAPT 287/4885POLB 3248/4885ATM 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.